IBI343 plus sintilimab and chemo for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that can't be removed with surgery or has spread.
- You haven't received any systemic therapy (chemotherapy or other cancer drugs that travel through your bloodstream) for this cancer.
- Your tumor tests positive for CLDN18.2, a specific protein marker.
- You are between 18 and 75 years old.
- Your daily activities are not significantly limited (ECOG performance status 0 or 1).
- Your tumor is not HER2-positive (a different protein marker that would require other treatments).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.